All posts by : Felistas

Scientists discovered that a previously uncharacterized subset of immune cells may play a critical role in the development of allergic diseases and explain differences between urban and rural populations. The finding, published in the journal Allergy, provides new insight into how the immune system is shaped in early life—and why urban children are more prone to allergies than children from rural areas.

When we hear the word “dementia,” we usually think of memory loss in older adults. But there’s another, much rarer form of the disease that strikes far earlier in life—childhood dementia, also known as Batten disease.

Childhood overweight and obesity are a growing public health challenge in South Africa. In 2016, 13% of the country’s children were reported to be obese. This is predicted to double by 2030.

Biomedical engineers at Duke University have developed a novel imaging system that harnesses the power of artificial intelligence to visualize individual retinal cells better than more expensive technologies. This advance could greatly enhance modern medicine’s diagnostic and monitoring capabilities for a range of diseases.

Smartwatches and other wearable devices can feel almost magical. Strap on a Fitbit, Apple Watch or Samsung Gear and you’re suddenly presented with a stream of data generated by—and about—your body: step counts, heart rate, blood oxygen level, calories burned and more.

Personalized feedback interventions (PFIs), a common strategy for helping college students moderate their alcohol use, can reduce drinking and its negative consequences. But such interventions vary by length and complexity, and targeting them strategically—considering users’ level of attentiveness—is an important determinant of outcomes, a new study has found.

Individuals who lived with obesity as children are less likely to be in work or studying in their mid-20s than their peers, new research presented at the European Congress on Obesity (ECO 2025) has found.

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding bevacizumab to first-line chemotherapy for patients with ovarian cancer, consistent with previous clinical trials. The findings are published online in the journal Cancer.

New research presented at the European Congress on Obesity (ECO2025) in Malaga, Spain (11–14 May) reveals that adverse waist-to-height ratio trajectories (a marker for central obesity) during childhood may increase cardiometabolic and cardiovascular risk at 10 years old.

A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk’s Wegovy.